

Application No. 09/623,006
Amdt. Date July 15, 2003
Reply to Official Action of April 9, 2003

Amendments to the Claims

The listing of the claims will replace all prior versions, and listings, of claims on this application:

Listing of Claims:

Claim 1 (Currently Amended) A method for inhibiting lipid oxidation associated with a condition in a patient ~~of treating conditions associated with lipid oxidation~~, comprising: administering to a patient a composition comprising a pharmacologically effective amount of an apolipoprotein (apo) A-IV compound to inhibit lipid oxidation, wherein the apolipoprotein A-IV compound is a peptide sequence of from 6 to 71 amino acids in length and has substantially the same lipid oxidation properties as the apolipoprotein A-IV compound.

Claims 2-3 (Cancelled)

Claim 4 (Currently Amended) A method according to claim 1 wherein the peptide has an amino acid sequence ~~selected from the group~~ comprising:

~~Met Phe Leu Lys Ala Val Val Leu Thr Val Ala Leu Val Ala Ile Thr Gly Thr Gln Ala Glu Val Thr Ser Asp Gln Val Ala Asn Val (SEQ ID NO:1);~~

~~Met Trp Asp Tyr Phe Thr Gln Leu Ser Asn Asn Ala Lys Glu Ala Val Glu Gln Leu Gln Lys Thr Asp Val Thr Gln Gln Leu Asn Thr Leu Phe Gln Asp Lys Leu Gly Asn Ile Asn Thr Tyr Ala Asp Asp Leu Gln Asn Lys Leu Val Pro Phe Ala Val Gln Leu Ser Gly His Leu Thr Lys Glu Thr Glu Arg Val Arg Glu Glu Ile Gln Lys Glu Leu Glu Asp Leu Arg Ala Met Val Ile (SEQ ID NO:2);~~

~~Met-Leu-Pro-His-Ala-Asn-Lys-Val-Ser-Gln (SEQ ID NO:3);~~

~~Met-Phe-Gly-Asp-Asn-Val-Gln-Lys-Leu-Gln-Glu-His-Leu-Arg-Pro-Tyr-Ala-Thr-Asp-Leu-Gln-Ala-Gln-Ile-Asn-Ala-Gln-Thr-Gln-Asp (SEQ ID NO:4);~~

~~Met-Lys-Arg-Gln-Leu-Thr-Pro-Tyr-Ile-Gln-Arg (SEQ ID NO:5);~~

~~Met-Gln-Thr-Thr-Ile-Gln-Asp-Asn-Val-Glu-Asn-Leu-Gln-Ser-Ser (SEQ ID NO:6);~~

~~Met-Val-Pro-Phe-Ala-Asn-Glu-Leu-Lys-Glu-Lys-Phe-Asn-Gln-Asn (SEQ ID NO:7);~~

~~Met-Glu-Gly-Leu-Lys-Gly-Gln-Leu-Thr-Pro-Arg-Ala-Asn-Glu-Leu-Lys-Ala-Thr-Ile-Asp-Gln-Asn-Leu-Glu-Asp-Leu-Arg-Ser-Arg-Leu-Ala-Pro-Leu-Ala-Glu-Gly-Val-Gln-Glu-Lys-Leu-Asn-Ile-His-Gln (SEQ ID NO:8);~~

~~Met-Glu-Gly-Leu-Ala-Phe-Gln (SEQ ID NO:9);~~

~~Met-Lys-Lys-Asn-Ala-Glu-Glu-Leu-His-Thr-Lys-Val-Ser-Thr-Asn-Ile-Asp-Gln-Leu-Gln-Lys-Asn-Leu-Ala-Pro-Leu-Val-Glu-Asp-Val-Gln-Ser-Lys-Leu-Lys-Gly-Asn-Thr-Glu-Gly-Leu-Gln-Lys-Ser-Leu-Glu-Asp-Leu-Asn-Lys-Gln-Leu-Asp-Gln-Gln-Val-Glu-Val-Phe-Arg-Arg-Ala-Val-Glu-Pro-Leu-Gly-Asp-Lys-Phe-Asn (SEQ ID NO:10);~~

~~Met-Ala-Leu-Val-Gln-Gln (SEQ ID NO:11);~~

~~Met-Glu-Lys-Phe-Arg-Gln-Gln-Leu-Gly-Ser-Asp-Ser-Gly-Asp-Val-Glu-Ser-His-Leu-Ser-Phe-Leu-Glu-Lys-Asn-Leu-Arg-Glu-Lys-Val-Ser-Ser-Phe (SEQ ID NO:12);~~

~~Met-Ser-Thr-Leu-Gln-Lys-Lys-Gly-Ser-Pro-Asp-Gln-Pro-Leu-Ala-Leu-Pro-Leu-Pro-Glu-Gln-Val-Gln-Glu-Gln-Val-Gln-Glu-Gln-Val-Gln-Pro-Lys-Pro-Leu-Glu-Ser (SEQ ID NO:13);~~

~~derivatives, analogs, homologs, fragments and mixtures thereof~~ or a derivative, analog, homolog, or fragment of said sequence, or a mixture of said amino acid sequences, wherein the derivatives, analogs, homologs, fragments and mixtures have substantially the same lipid oxidation properties as the peptide.

Claim 5 (Previously Amended) A method according to claim 1 wherein the composition further comprises at least one ingredient selected from the group consisting of carriers, fillers, and excipients.

Claim 6 (Previously Amended) A method according to claim 1 wherein the composition further comprises a lipophilic compound.

Claim 7 (Original) A method according to claim 6 wherein the lipophilic compound is selected from the group consisting of organic solvents, phosphatidyl choline, cholesterol and mixtures thereof.

Claim 8 (Previously Amended) A method according to claim 1 wherein the administering comprises oral administering.

Claim 9 (Previously Amended) A method according to claim 1 wherein the administering comprises parenteral administering.

Claim 10 (Original) A method according to claim 9 wherein the administering is a dosing method selected from the group consisting of transdermal administering, subcutaneous injecting, intravenous injecting, intraperitoneal injecting, intramuscular injecting, intrasternal injection, intrathecal injection, intraventricular injecting, intracerebroventricular injecting, and infusing.

Claim 11 (Currently Amended) A method according to claim 1 wherein the composition is administered to a patient in a unitary dose of from about 1 to about 1000 mg.

Claim 12 (Currently Amended) A method according to ~~claims~~ claim 11 wherein the unitary dose ~~in~~ is administered to the patient from ~~about~~ 1 to about 3 ~~time~~ times a day.

Claim 13 (Original) A method of inhibiting the progression of atherosclerosis in a patient in need thereof comprising administering to the patient an effective anti-oxidation amount of a compound of claim 1.

Claim 14 (Previously Amended) A method of treating a patient for atherosclerosis comprising administering to the patient an effective anti-oxidation amount of a compound of claim 1.

Claim 15-18 (Cancelled)

Claim 19 (Currently Amended) The method of claim 1 wherein said peptide comprises:
Met-Lys-Arg-Gln-Leu-Thr-Pro-Tyr-Ile-Gln-Arg (SEQ ID NO:5)[[;]].

Claims 20-62 (Cancelled)